Developmental pathway for potent V1V2-directed HIV-neutralizing antibodies
Nicole A. Doria‐Rose(National Institutes of Health), John R. Mascola(National Institute of Allergy and Infectious Diseases)
Cited by 749
Related Papers
Efficacy of the mRNA-1273 SARS-CoV-2 Vaccine at Completion of Blinded Phase
|New England Journal of Medicine|2021|661
Two Randomized Trials of Neutralizing Antibodies to Prevent HIV-1 Acquisition
|New England Journal of Medicine|2021|540
Preserved CD4+ Central Memory T Cells and Survival in Vaccinated SIV-Challenged Monkeys
|Science|2006|367
Next-generation influenza vaccines: opportunities and challenges
|Nature Reviews Drug Discovery|2020|333